Thymosin Alpha 1
Also known as: Ta1, Thymalfasin, Zadaxin
Synthetic Thymic Hormone | Immune System Modulator
Overview
Thymosin Alpha 1 is a synthetic 28-amino acid peptide identical to naturally occurring thymic hormone, studied in 11,000+ patients across 30+ clinical trials with less than 1% serious adverse events. Approved in 35+ countries for immune modulation.
Key benefits
- Primary FDA-studied route with extensive clinical validation
- Maximum immune modulation through systemic circulation
- Established dosing from 35+ countries of clinical use
- Exceptional safety profile (<1% serious adverse events)
- Reduces pro-inflammatory cytokines 40-60%
- Approved in 35+ countries
Mechanism of action
Activates TLR pathways, enhances T-cell maturation, stimulates NK cells, and modulates dendritic cell function via systemic circulation. Injectable route achieves 90-95% bioavailability with 2-hour peak time.
Molecular data
- Type
- Acetylated polypeptide
- Half-life
- ~2 hours
Sequence
Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn
Indications
What the research community uses this compound for, with self-reported effectiveness.
Immunity
Inflammation
Recovery
Anti-Aging
Dosing protocols
Common protocols by delivery method. Adjust the curve below to model accumulation in your own cycle.
Delivery method
| Protocol | Dose | Frequency | Duration |
|---|---|---|---|
| — | 1.6mg | 2x weekly | — |
| — | 1.6mg | 2x daily for 5 days, then daily | — |
| — | 1.6mg | 2x weekly | — |
| — | 1.6mg | 2x weekly | — |
Delivery method
| Protocol | Dose | Frequency | Duration |
|---|---|---|---|
| — | 500mcg per nostril | 2x daily | — |
| — | 1000mcg per nostril | 2x daily | — |
| — | 500mcg per nostril | 1x daily | — |
Safety
Reported adverse effects, contraindications, and what to monitor on cycle.
Common side effects
- Mild injection site reactions (<10% incidence)
- Generally well-tolerated with exceptional safety record
Contraindications
- Organ transplant recipients (risk of graft rejection)
- Pregnancy and breastfeeding
Monitoring
- Monitor for hypersensitivity with first dose
- Watch for first-dose immune activation symptoms
References
Primary literature and clinical-trial data informing this entry.